๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Nuvation Bio Inc. (NUVB)
NYSE: NUVB ยท Real-Time Price ยท USD
3.800
-0.010 (-0.26%)
At close: Nov 20, 2026, 4:00 PM EST
3.792
-0.008 (-0.21%)
After-hours: Nov 20, 2026, 7:30 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

IBTROZI sales grew 18% QoQ despite fewer ROS1 alerts, while management highlighted durable responses and a potential revenue-stacking opportunity. Safusidenib data are expected in 2027, alongside DDC platform updates and selective BD.

Farzin Haque
Biotech Analyst, Jefferies

Hi, everyone. My name is Farzin Haque, one of the biotech analysts at Jefferies. It is my pleasure to introduce David Hung, CEO, and Philippe Sauvage , CFO of Nuvation Bio. Maybe, David, you can start off giving a quick one-minute intro to the company.

David Hung
CEO, Nuvation Bio

Yeah. We have, I guess, focus on three programs. IBTROZI is a commercial-stage asset approved a year ago in the U.S., also approved in China and Japan, and about to be approved in Europe. We have had about a year of sales, and we are already a market leader in our space. We are also a market leader in first-line patients. If you look at our quarter-on-quarter growth in the last quarter, it was up 18% in spite of a 20% drop in new patient alerts in testing for ROS1.

I would say we are about $100 million for the year so far, and I think that if you look at our data, our 90% response rate and 50-month duration of response have not been matched by anyone in the first-line space. In the second-line indication, our 56% response rate and 66% intracranial response rate have not been matched by anyone in the second-line indication. If you look at our tolerability and safety, we are now the only brain-penetrant ROS1 TKI that does not have a CNS warnings and precautions.

I would say that that program is going very well. Our second program, safusidenib, is a mutant IDH1 glioma drug. We are in four studies right now. Unlike the only competitor in the space, vorasidenib, which is approved only in the low-grade glioma indication, we have shown activity in both low-grade and high-grade glioma. If you look at vorasidenib's most recent three-year data, in the low-grade indication, their response rate was 21%. In the same indication, our response rate was 52%. If you look at their progression-free survival at three years, in the low-grade indication, it was 52% PFS.

Ours was 79%. We think that this drug is extremely active in the low-grade indication. If you look at vorasidenib's response in high-grade glioma, it was 0%. Ours was 17%, with a third of those being complete responses. Again, we believe that safusidenib is extremely active in low-grade setting as well as the high-grade setting. We are in a number of trials. Our earliest data will read out in 2027.

We are going to see grade three oligo patients, a form of high-grade glioma, that we will start to have data in the second half of next year. We are also enrolling patients in a post-vorasidenib failure indication. That is clearly a really big indication, and we will also have some data in that indication probably in the second half of next year. Then we have two other trials reading out with a PFS endpoint later on in 2029.

But our first data on response rate will start to read out in the second half of next year. We believe that if you look at the precedent set by companies like Chimerix, where their drug was approved on 11 responses in 50 patients, we think 20% or so response rate or higher is potentially sufficient to get approval in an indication where there is no other therapy. And given the activity that we've seen with safusidenib in both the low-grade and high-grade indications, we think that we're very bullish on that program.

Our third program is a drug-drug conjugate program. DDCs are like an ADC without the A, so no antibody. We're fusing two small molecules together. Because small molecules are so much smaller than antibodies, they can go places that antibodies can't go, and they can also do things that antibodies and antibody drug conjugates can't do. I think a very exciting example of a DDC, actually the only company that we are aware of that has a program like ours, is Halda.

As you know, Halda's prostate drug, based on 10 patients of data, was acquired for $3 billion, and they just recently announced post-existing response rates of 69%. Their molecule is basically a DDC. We have an entire platform based around this DDC concept, and we're going to be making an announcement on that program in the next six weeks or so. A very brief announcement, and then we're going to follow that up with an R&D day earlier next year. So, we think that's an extremely exciting platform technology that could yield many molecules to the pipeline.

Farzin Haque
Biotech Analyst, Jefferies

Makes sense. I want to start with the safusidenib, because I think that's the clear value driver in the future. So if it works across the newly diagnosed, recurrent, high-grade, post-VORA, how should we think about the addressable patient population? Which one is the biggest driver for the commercial opportunity?

David Hung
CEO, Nuvation Bio

So, if you look at the division of low-grade and high-grade glioma among brain tumors, it's about 50/50. But the difference is, IDH1 mutations make patients actually live longer. So if you look at the progression-free survival of IDH1 mutant brain tumors, it's actually extremely long compared to non-IDH1 driven. But IDH1 is also relentless, so they will always continue to grow. So low-grade patients can live 20plus years. Even high-grade IDH1 mutant gliomas like astrocytoma, even GBM, they can still live six-plus years, unlike regular GBM. So, what's unique about IDH1 as a mutation is that it makes the tumor relentless, but it also makes the patient survive for long periods of time.

You do need to treat these tumors because, especially when they occur in younger patients, and they will grow relentlessly, they will compromise things like your neuro status, your vision, your hearing, all the things that you expect brain tumors to do. It is very important that you address it. You cannot give repeated surgeries to young patients. You cannot just keep cutting out parts of the brain.

You cannot continually give radiotherapy, which is clearly very damaging to brain tissue. You cannot give chemotherapy. No patient wants to take chemotherapy forever. You do need an oral therapy. We think our once-a-day pill is a very attractive option, and we can show that we continue to have the results that we have shown so far. The reason the market opportunity is so large is because when you have 20 years of patients taking the drug, you are talking about a revenue stacking opportunity you just do not see in general in oncology.

That is in the low-grade setting. In the high-grade setting, even though it is shorter than low-grade, we are still talking about up to six-plus years in the high-grade setting, so that is still an attractive option. Even though the roughly 50/50 split of high-grade to low-grade is how the indications break out, the longer duration of therapy likely in low-grade indications makes that a more compelling commercial opportunity. When I mentioned earlier that vorasidenib has a 21% response rate in low-grade, we have a 52% response rate in low-grade.

When people ask us, "Why do we believe this drug will work after vorasidenib?" Well, we have 31 percentage points more response rate in the same indication. We do believe SAFU will work after vorasidenib. We believe that if it works after vorasidenib, people will use it after vorasidenib, and even instead of vorasidenib. We actually believe that is the path to get the entirety of the lower market.

Farzin Haque
Biotech Analyst, Jefferies

Maybe to rephrase that, like, mechanistically, how SAFU works differently from VORA to give that differential responses?

David Hung
CEO, Nuvation Bio

We've made the point before that, even though they both hit IDH1, we are seeing activities with safusidenib that you don't see with vorasidenib. vorasidenib's main adverse event is liver function test abnormalities. We don't generally see that. If you look at our adverse events, even though almost all of them are grade one, we do see, out of our top seven adverse events, five of them are immune-related. We see things like alopecia, rash, arthralgia, like rheumatoid arthritis, pruritus. We believe that if you look at our responses, they take 6-12 months to kick in, sometimes even longer. In fact, even between years two and year three, we had an additional 8% response rate, going from 44% - 52% in our recent publication.

When you see those really long times to responses, and then really durable responses, we have a GBM that's been in the CR for three and half years. We have another high-grade oligodendroglioma that's been gone for two years. When you see those really long onset to response, and then very durable responses, it's very reminiscent of immuno-oncology agents. We actually believe that safusidenib has a significant immune component to its activity, and we believe that that differentiates it from VORA and why we believe we will see responses after VORA failure. Also, we're already seeing responses in indications that VORA's response rate is zero.

Farzin Haque
Biotech Analyst, Jefferies

Got it. Any color on the enrollment across SIGMA, the oligodendroglioma study, and the post-VORA study?

David Hung
CEO, Nuvation Bio

We haven't given any guidance to the street, but I would say that all the studies have been enrolling very well. We've committed publicly that we will have a minimum of 20 grade three oligodendroglioma patients enrolled by this year, and we are absolutely on track for that. If you look at the post-VORA failure study, which is one of the earlier studies to read out, the reason that's so attractive is that Servier has now treated thousands of patients with VORA. If you look at the progression rate on vorasidenib, 23% of patients in the INDIGO study progressed at one year. There are thousands of patients who've already failed VORA and will continue to fail. We believe we need to enroll 50 of those patients and show 10 responses to be in a position to take that to the FDA for a potential consideration of approval.

I think that there are a lot of patients who are failing vorasidenib. That study should enroll very quickly. We are already on track to get the grade three oligodendrogliomas that we have already committed publicly, and we will probably exceed that target. I think that is a testament to how many of these patients there are and the size of the commercial opportunity.

Farzin Haque
Biotech Analyst, Jefferies

Is there a combination of the patient number, confirmed responses, and follow-up for the 20% benchmark that you mentioned, like to have the conversations with the FDA for a path?

David Hung
CEO, Nuvation Bio

Yeah. If you look at Chimerix, I think they had 50 patients in their pivotal study. They had 11 responses, 22% response rate, and they were approved. I think that we have said, what the FDA wants to see is that your confidence interval between your response rate does not overlap with the response rate of the other available therapies, which in this case would be chemotherapy with a mid-single-digit response rate. We do think that somewhere in the ballpark of 20% response is enough to have non-overlapping confidence intervals to get approval. Then, duration of response needs to be something that FDA considers meaningful. We have not really talked publicly about what that number is, but I think a lot of people figure that is just a number of months.

These are patients who are young, they are progressing relentlessly, they are going to do badly if they are not treated, so I think that is a very, very unmet need. The data that we have shown, 52% response rate, low grade with 79% PFS at three years, I mean, that certainly would beat the bar, I would think.

Farzin Haque
Biotech Analyst, Jefferies

For the standard of care, is it like more six months for the duration of response?

David Hung
CEO, Nuvation Bio

No, I think that people use that number often, but again, we haven't released.

Farzin Haque
Biotech Analyst, Jefferies

Okay. For the post-vora, you mentioned that it could enroll faster, but you're guiding to both data sets most likely in second half 2027. Is that-

David Hung
CEO, Nuvation Bio

Yeah, we haven't given any guidance on that. I do think that there are thousands of patients at this point who have failed vora. As I said, we need 50 of them, and we need to see about 20% responses, so hopefully around 10 patients or more. I think that would do the trick. So, we do think that trial will enroll pretty quickly. We think that we're already getting lots of inbounds for patients who want to be on the trial, just given the data we've presented publicly so far. So, I do think that there's a lot of interest in that trial, and it will enroll well.

Farzin Haque
Biotech Analyst, Jefferies

Got it. One of the things is that you just mentioned that there's a delayed response sometimes. How could that complicate FDA's interpretation of the efficacy?

David Hung
CEO, Nuvation Bio

Well, I think whatever response rate we do report, it's only going to get better from there. The responses can kick in. I think our earliest response we've ever seen is around two weeks, but most of the responses kick in at 6-12 months. As I mentioned, between years two and year three, we had 8% more responses in our Daiichi study. So, these patients can continue to improve for years after their initial responses. So, we do think that we'll take the data that we have next year and start to talk to FDA about that, but we would anticipate whatever number we put out, that will probably improve over the subsequent years.

Farzin Haque
Biotech Analyst, Jefferies

Is there a benchmark, similarly 20% for post-vora

David Hung
CEO, Nuvation Bio

I think that 20% is that we know that Chimerix was approved on a 22% response rate, so I think that's if we had to give a precedent, that would be a reasonable one.

Philippe Sauvage
CFO, Nuvation Bio

Just to reiterate on what David was doing, the 20% is because of 50 patients if you want, and that's 10, the 11ths of Chimerix. What the FDA wants to see is just separation. So, if your response rate is higher, theoretically, they need to see less patients, because you just want to see...

David Hung
CEO, Nuvation Bio

Exactly.

Philippe Sauvage
CFO, Nuvation Bio

...statistical separation from the single-digit response rate of chemo. That's true for both scenarios, the post-vora and oligo, just like the grade [three, four,] and Hodgkin lymphoma, because in both cases, there is nothing else but salvage chemo.

Farzin Haque
Biotech Analyst, Jefferies

Makes sense. Okay, switching gears to IBTROZI. That market is considered, the ROS1 market is considered niche by many, but how do you see the long-term opportunity unfolding as you have launched into the

David Hung
CEO, Nuvation Bio

The market is niche in terms of how many new patients are diagnosed a year. It's about 3,000 patients. If you multiply that times the drug price, that's still about $1 billion a year in the theoretical maximum potential of that opportunity. What's unique about ROS1 is that with IBTROZI, our duration of response is 4.2 years.

That means that every patient in year one, let's say we have 3,000 patients who get drug, and that's about $1 billion. That means everyone in year one will likely go to year two, where you'll have another 3,000 new patients, so that will stack to $2 billion. By the year three, you'll have $3 billion. By year four, you'll have $4 billion. So, even for a 3,000-patient incidence indication, it's still potentially a pretty large commercial indication because of the revenue stacking. You don't see generally 4.2 years of DOR for most drugs.

Most people are pretty happy if your duration of response is in the 6-12 month range. So, I think that having such a long DOR and a 90% response rate, which has not been matched by many drugs in any oncology indication with any drug, I think makes this a very uniquely attractive commercial opportunity.

Farzin Haque
Biotech Analyst, Jefferies

Okay. In third quarter, you had a softness with the new patient starts and also with the NGS testing. Is that something, a temporary softness or more of a structural change in how the disease is being diagnosed and treated?

David Hung
CEO, Nuvation Bio

We buy new patient alerts for new ROS1 diagnoses from all the testing labs. In the last quarter, there was a 20% drop in new alerts. But in rare indications, that just happens. We know that there was also a 14% drop in KRAS in this last quarter. In the previous quarter, there was a 19% drop in ALK diagnoses. When you have rare mutations, 10 patients here or there can really change the testing rate, the diagnosis rate. We don't think that it's any trend. We just think it's lumpiness. But the most important thing is that in spite of a 20% drop in new patient diagnoses in that quarter, we still grew sales 18% in spite of that. Of course, it would have been higher than that had there been 20% more diagnoses.

We still grew over the previous quarter 18%, and we're still market leader, and we are also first-line share leader. I think we're doing well. Clearly, I think that will equilibrate over time, so we don't expect that that's indicative of any change in how this drug is working or how the disease is being diagnosed.

Farzin Haque
Biotech Analyst, Jefferies

The community testing remains one of the key upside levers. Now that you are six quarters into the launch, have you seen any measurable increase in the NGS testing with the DNA/RNA?

David Hung
CEO, Nuvation Bio

We have made a concerted effort to actually look at centers where testing rates are on the low side. With our efforts, we have actually been able to, at least in one center, double its testing rate and another one triple it. We actually have made some strides in changing testing rates in large community centers. Academic centers, their testing rate is close to 100%, so there is not much room for improvement there.

But in the community setting, there is room for improvement, especially now with some of these large aggregators where they control many patients in many states. If you can change testing rates there, that clearly will have great ramifications for the product. We are making a significant effort to educate centers on that, and we have had success in the centers that we have approached.

Farzin Haque
Biotech Analyst, Jefferies

One of the common questions I get is, of course, the BMS market entry. There seems to be a disconnect, but IBTROZI is the only one that does not have the CNS warning on the label. Do you think the doctors, investors, there is a disconnect, but do you think doctors understand the nuance between the two drugs, their profiles?

David Hung
CEO, Nuvation Bio

I think that they need to read the labels. The BMS drug is approved in the second-line setting.

Farzin Haque
Biotech Analyst, Jefferies

Second-line setting.

David Hung
CEO, Nuvation Bio

If you look at the second-line response rate of that drug, it is 49%. Ours is 56%. So that is the label. If you look at the intracranial response rate for that drug, it is 48%. We are 66%. So just apples to apples in the second-line indication, not really that close. The other thing is that if you look at the, on the safety side, not only is there a CNS warnings and precautions with that, but that is with only 14% of patients having one-year follow-up.

We have four times that level of follow-up. So adverse events only accumulate with more time. So we expect those adverse events to grow further. If you look at where we are right now with no CNS warnings and precautions, I think I mentioned previously that out of our top six adverse events, out of 337 patients, we only had one discontinuation.

We think that IBTROZI's efficacy is not only by far the best with a 90% response rate and 15-month duration of response, but our safety and tolerability also have not been matched. We think we are in a good position.

Farzin Haque
Biotech Analyst, Jefferies

One of the other things is that it is a second-line label, they are going to expand to the frontline label. We do not know when. Maybe second half 2027.

David Hung
CEO, Nuvation Bio

Yep.

Farzin Haque
Biotech Analyst, Jefferies

Is there any reason to believe that the label will change? If anything, it should get worse.

David Hung
CEO, Nuvation Bio

I think the AEs will get worse, for sure.

Farzin Haque
Biotech Analyst, Jefferies

Okay.

David Hung
CEO, Nuvation Bio

The thing is that even by next year, there won't be the length of follow-up that we have. So no one's going to have a 15-month follow-up, much less duration of response. Our duration of response is 15 months. I think it's going to be hard to beat. Our response rate is 90%. That's going to be hard to beat. So I just think that it's going to be difficult to overtake IBTROZI.

Farzin Haque
Biotech Analyst, Jefferies

You also have the adjuvant study, which they're not running. What makes you believe that the investors should, not investors, investigators should be interested to enroll the study, and how is that enrollment going?

David Hung
CEO, Nuvation Bio

You make an interesting point that we're actually the only ROS1 TKI being developed in the adjuvant setting. In order to be given that early in treatment of a patient, you have to be incredibly well tolerated.

Because we are incredibly well tolerated, that study's enrolling beautifully, and we are going to be the only ROS1 TKI with an adjuvant label, we believe. That said, I think that that increases the market even further. I think we've estimated about 30% larger commercial opportunity by moving to the adjuvant setting.

And we also, when we look at the RET study with selpercatinib, the hazard ratio of 0.17 in the LIBRETTO-432 study is really extraordinary and gives us even more confidence that this study will not only be positive, but will actually read out sooner than we previously anticipated. We believe that the RET study, the LIBRETTO-432 study, is an example of what a great drug does in the adjuvant setting, and we believe that will reflect exactly the same way in the IBTROZI adjuvant study.

Farzin Haque
Biotech Analyst, Jefferies

Makes sense. A year from now, hopefully we'll all be back. What would need to be true for you to say that IBTROZI has meaningfully exceeded your expectations?

David Hung
CEO, Nuvation Bio

I think if we just see the revenue stacking and the new patient share that we've talked about, I think it's all a first-line game. Whoever wins first line wins the entire thing.

Farzin Haque
Biotech Analyst, Jefferies

Right.

David Hung
CEO, Nuvation Bio

So, with our duration of response, we would expect to see that revenue stacking that we're talking about. I think that would make us feel that we've done a good job in executing it. Given the fact that in 12 months we've gone from nothing to majority market share and first-line leader, I think our commercial team has done a great job, and I think we will continue to execute.

Farzin Haque
Biotech Analyst, Jefferies

Okay. On the BD front, you guys have a strong balance sheet, and you have successfully integrated the AnHeart acquisition. So what is the current appetite and capacity for in-licensing or even M&A?

Philippe Sauvage
CFO, Nuvation Bio

Well, like you said, Farzin, we have $660 million of cash till last quarter, which puts us in a very comfortable position. We had enough cash to get to profitability prior to our convert raise back in June, so that gives us even more firepower. We are going to be very selective, but we're always actively looking. We think it's healthy for any biotech to confront itself to the rest of the market and to see what's out there and how good it can be, and how good it can be as an add-on to your company as well.

So, we're looking at things. We also have a base of operation in China, which is helpful to look at certain opportunities as well. So we'll see. We've not done anything yet because we didn't find anything which was good for us at the appropriate price, but who knows? We might.

David Hung
CEO, Nuvation Bio

I think these brutal market conditions in the last few months, given the fact that we have so much cash on our balance sheet, will further differentiate us from our peer group, and I think allow us to look at even more opportunities on the BD front. So I think that's potentially a really interesting opportunity for us.

Farzin Haque
Biotech Analyst, Jefferies

I want to touch on the DDC update that you're going to have by year end. Any high-level attributes of the platform, like target selection, payloads, and tumor focus that you can give?

David Hung
CEO, Nuvation Bio

We're not going to give that level of detail this year, but we intend to give that level of detail in our R&D day in the beginning part of next year.

Farzin Haque
Biotech Analyst, Jefferies

Okay. This year will be more of a-

David Hung
CEO, Nuvation Bio

Just tell you where we are and what we're doing with the program, because there's been no update for a long time now. We're going to tell you what we're going to do and where the program is, but next year we want to talk in more detail about exactly what we're doing and why and how.

Farzin Haque
Biotech Analyst, Jefferies

The Halda one that you explained was an interesting one, because that led to a lot of stocks being moving because of the data, even in prostate and other ones.

David Hung
CEO, Nuvation Bio

Yeah.

Farzin Haque
Biotech Analyst, Jefferies

But how do you envision in the longer run, like, would it be more of a BD or would you develop it in-house? Maybe a little bit.

David Hung
CEO, Nuvation Bio

I mean, all of our DDCs have been made in-house.

Farzin Haque
Biotech Analyst, Jefferies

Completely in-house.

David Hung
CEO, Nuvation Bio

This was the platform that actually was the basis upon which I founded Nuvation Bio in 2018. We've been thinking about this for a long time. There are many, many things to consider in doing it. The chemistry is quite difficult, but the Halda molecule is a very good example of how they've coupled an AR molecule to a BET inhibitor, and that molecule has really quite remarkable activity.

Farzin Haque
Biotech Analyst, Jefferies

Yeah

David Hung
CEO, Nuvation Bio

As I said, it led to a $3 billion acquisition for 10 patients' worth of data. We think that's a testament to how promising this platform is. We have many, many programs in our DDC platform, and we're going to announce a little bit of the beginning part of that and talk about what we're doing, but we are very excited about the program. We're going to clearly try to go where people haven't gone yet, because we don't want to be following another program, so we have a pretty exciting platform that we think we're going to start talking about in detail in the first half of next year.

Farzin Haque
Biotech Analyst, Jefferies

We're almost out of time. Maybe to wrap up, we know the cash, but what are the key catalysts that investors should be focused on over the next six to 12 months?

David Hung
CEO, Nuvation Bio

I think they should look at continuing IBTROZI sales. I think we should do well there. Look at SAFU updates, see what the response rate data are in 2027. The DDC update, especially with the R&D day, you'll get more of an understanding of what we're actually doing and why it's so promising. Then look for any other, if there's any BD or other opportunities that we decide to bring in-house.

Farzin Haque
Biotech Analyst, Jefferies

Always great chatting with you guys. Thank you so much for your time, sir.

David Hung
CEO, Nuvation Bio

Thanks so much, Farzin.

Philippe Sauvage
CFO, Nuvation Bio

Thanks, Farzin.

Farzin Haque
Biotech Analyst, Jefferies

Thank you.